New blood-thinning drug approved by FDA

Posted on 2009-07-22 10:05:32 in Cardio-Vascular | Longevity and Age Management | Medications | Stroke |

Angioplasty, a procedure in which a stent is inserted into a blood vessel to open an artery that has been clogged due to atherosclerotic plaque, is widely used to save lives of heart attack victims and others suffering from coronary artery disease. However, it is not without serious complications, one of which is the potential formation of blood clots caused when platelets in the blood clump around the procedure site. This can lead to heart attack, stroke and even death.

Now, Eli Lilley and Company of Indianapolis, in partnership with Tokyo-based Daiichi Sankyo Ltd., has received approval by the FDA to market a new blood-thinning drug called Effient, which comes in tablet form, to reduce the risk of blood clots forming in patients who have undergone angioplasty. Prior to approval, Effient (also known by the generic name prasugrel) was the focus of a trial involving 13,608 patients to compare its success rate against Plavix, another commonly prescribed blood-thinning drug. All of the study participants had either had a heart attack threat or an actual heart attack and were about to undergo angioplasty.

In patients receiving Effient, the number who had subsequent non-fatal heart attacks was 7 percent, compared to 9.1 percent in patients receiving Plavix. However, patients with a history of stroke who were given Effient were more likely to have another stroke while taking the drug. And patients taking Effient also had a greater risk of significant and sometimes fatal bleeding. As a result, Effient will carry a boxed warning alerting doctors and patients to the risk of serious bleeding associated with the drug.

"Effient offers physicians an alternative treatment for preventing dangerous blood clots from forming and causing a heart attack or stroke during or after an angioplasty procedure," says John Jenkins, director of the Office of New Drugs, in the FDA's Center for Drug Evaluation and Research. "Physicians must carefully weigh the potential benefits and risks of Effient as they decide which patients should receive the drug."

News Release: FDA approves Effient to reduce risk of heart attack in angioplasty patients www.news.xinhuanet.com July 11, 2009

Health Headlines MORE »

Fiber May Reduce Breast Cancer Risk
For every 10 g per day increase in soluble fiber intake, a woman may reduce her risk of breast cancer by up to 26%.
Soy Protein Boosts Brain Function
Peptides from soybeans modulate neurotransmitters, thereby helping to boost circulation in the brain.
Pepper Compounds for Weight Management
Capsaicin (found in hot peppers) and capsiates (present in sweet peppers) exert modest weight management benefits.
Americans Lag in Preventive Screenings
While over 20% of U.S. adults receive periodic health examinations each year, many do not receive recommended preventive screening tests and counseling services
The Stress – Obesity Connection
Researchers from Norway suggest a mechanism by which stress may make a person fat, and being obese may create stress.
Lack of Sleep Triggers Hunger
Swedish researchers report that people who are short on sleep experience greater levels of hunger.
Knock Out Anxiety
Among women with Generalized Anxiety Disorder (GAD), regular physical activity helps to reduce anxiety, irritability, feelings of tension, low energy and pain.
Magnesium Helps to Reduce Stroke Risk
For every 100 mg per-day increase in magnesium in the diet, stroke risk may decline by up to 9%.
Senior Runners Continue to Excel
The best male marathon runners over age 65, and the best female marathon runners over age 45, continue to consistently improve their performance.
Stem Cell Therapy Restores Vision
UCLA-led team safely uses human embryonic stem cells to treat macular degeneration.
Anti-Aging Forum Anti-Aging Forum Anti-Aging Forum Anti-Aging Forum
Anti-Aging textbook Anti-Aging Forum MLDP Anti-aging jobs Join A4M
ANTI-AGING TIP OF THE DAY
In Working Order
Men and women who stay mentally engaged in their original occupational field fare after retirement fare best mentally. University of Maryland (Maryland, USA) researchers studied 12,189 retired men and women, ages 51 to 61 years at the beginning of the study. The team revealed that those retirees who continued to work in a bridge job experienced fewer major diseases...
» MORE